A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs
1984; Wiley; Volume: 24; Issue: 4 Linguagem: Inglês
10.1002/j.1552-4604.1984.tb01822.x
ISSN1552-4604
Autores Tópico(s)Cardiac Arrhythmias and Treatments
ResumoThe Journal of Clinical PharmacologyVolume 24, Issue 4 p. 129-147 Free Access A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs E. M. VAUGHAN WILLIAMS D.M., D.Sc., F.R.C.P., E. M. VAUGHAN WILLIAMS D.M., D.Sc., F.R.C.P. University Department of Pharmacology, Oxford.Search for more papers by this author E. M. VAUGHAN WILLIAMS D.M., D.Sc., F.R.C.P., E. M. VAUGHAN WILLIAMS D.M., D.Sc., F.R.C.P. University Department of Pharmacology, Oxford.Search for more papers by this author First published: April 1984 https://doi.org/10.1002/j.1552-4604.1984.tb01822.xCitations: 619AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Williams Vaughan EM. Classification of anti-arrhythmic drugs. In: E Sandoe, E Flensted-Jansen, KH Olesen, eds. Symposium on Cardiac Arrhythmias. Sodertalje, Sweden: AB Astra; 1970: 449– 472. 2 Singh BN, Williams Vaughan EM. A fourth class of antiarrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovase Res. 1972; 6: 109– 119. 3 Szekeres L, Williams Vaughan EM. Antifibrillatory action. J Physiol. 1962; 160: 470– 482. 4 Johnson EA, McKinnon MG. The differential effect of quinidine and pyrilamine on the myocardial action potential at various rates of stimulation. J Pharm Exp Therap. 1957; 120: 460– 468. 5 Williams Vaughan EM. The mode of action of quinidine on isolated rabbit atria interpreted from intracellular potential records. Br J Pharmacol. 1958; 13: 276– 287. 6 Bigger JT, Mandel WJ. Effect of lidocaine on conduction in canine Purkinje fibers and at the ventricular muscle-Purkinje fiber junction. J Pharm Exp Therap. 1970; 172: 239– 254. 7 Davis LD, Temte JV. Electrophysiological actions of lidocaine on canine ventricular muscle and Purkinje fibers. Circ Res. 1969; 24: 639– 655. 8 Bassett AL, Hoffman BF. Anti-arrhythmic drugs: electrophysiological actions. Ann Rev Pharmacol. 1971; 11: 143– 170. 9 Singh BN, Williams Vaughan EM. The effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle. Circ Res. 1971; 29: 286– 296. 10 Williams Vaughan EM. Antiarrhythmic Action. London: Academic Press; 1980. 11 Watanabe Y, Dreifus LS, Likoff W. Electrophysiological antagonism and synergism of potassium and antiarrhythmic agents. Am J Cardiol. 1963; 12: 702– 710. 12 El-Sherif N, Scherlag BJ, Lazzara R, Hope RF. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 4. Mechanism of action of lidocaine. Circulation. 1977; 56: 395. 13 El-Sherif N, Lazzara R. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 5. Mechanism of action of diphenylhydantoin. Circulation. 1978; 57: 465– 472. 14 Rosen MR, Merker C, Gelband H, Hoffman BF. Effects of procaine amide on the electrophysiologic properties of the canine ventricular conducting system. J Pharm Exp Therap. 1973; 185: 438– 446. 15 Wittig JH, Harrison LA, Wallace AG. Electrophysiological effects of lidocaine on distal Purkinje fibers of canine heart. Am Heart J. 1973; 86: 69– 78. 16 Olsson SB, Cotoi S, Varnauskas E. Monophasic action potential and sinus rhythm stability after conversion of atrial fibrillation. Acta Med Scand. 1971; 190: 381– 388. 17 Arnsdorf MF, Bigger JT. Effect of lidocaine hydrochloride on membrane conductance in mammalian cardiac Purkinje fibers. J Clin Invest. 1972; 51: 2252– 2263. 18 Carmeliet E, Saikawa T. Shortening of the action potential and reduction of pacemaker activity by lidocaine, quinidine and procainamide in sheep cardiac Purkinje fibers. Circ Res. 1982; 50: 257– 272. 19 Coraboeuf E, Deroubaix E. Shortening effect of tetrodotoxin on action potentials of the conducting system in the dog heart. J Physiol. 1978; 280: 24P. 20 Colatsky TJ. Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. Circ Res. 1982; 50: 17– 27. 21 Birkhead JS, Williams Vaughan EM. Dual effect of disopyramide on atrial and atrio-ventricular conduction and refractory periods. Brit Heart J. 1977; 33: 657– 660. 22 Ronfeld RA. Comparative pharmacokinetics of new antiarrhythmic drugs. Am Heart J. 1980; 100: 978– 983. 23 Harrison DC, Winkle R, Sami M, Mason J. Encainide: a new and potent antiarrhythmic agent. Am Heart J. 1980; 100: 1046– 1054. 24 Campbell TJ. Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two steroidal antiarrhythmic drugs, CCI 22277 and ORG 6001. Br J Pharmacol. 1982; 77: 541– 548. 25 Campbell TJ, Williams Vaughan EM. Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, encainide and lorcainide. Cardiouasc Res. 1983; 17: 251– 258. 26 Campbell TJ. Kinetics of onset of rate-dependent effects of class 1 antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res. 1983; 17: 344– 352. 27 Campbell TJ. Resting and rate-dependent depression of maximum rate of depolarisation (Vmax) in guinea-pig ventricular action potentials by mexiletine, disopyramide and encainide. J Cardiovasc Pharmacol. 1983; 5: 291– 296. 28 Campbell TJ. Importance of physicochemical properties in determining the kinetics of the effects of class 1 antiarrhythmic drugs on maximum rate of depolarisation in the guineapig ventricle. Br J Pharmacol. 1983; 80: 33– 40. 29 Weidmann S. The effect of the cardiac membrane potential on the rapid availability of the sodium-carrying system. J Physiol. 1955; 127: 213– 224. 30 Williams Vaughan EM, Szekeres L. A comparison of tests for antifibrillatory action. Brit J Pharmacol. 1961; 17: 424– 432. 31 Williams Vaughan EM. Biophysical background to beta-blockade. In: DM Burley, JH Frier, RK Rondel, SH Taylor, eds. New Perspectives in Beta-Blockade. Horsham: CIBA; 1973: 11– 39. 32 Keren G, Tepper D, Butler B, Miura D, Aogaichi K, Somberg J. The efficacy of cibenzoline in preventing ventricular tachycardia induced by programmed electrical stimulation in the dog. J Clin Pharmacol. In press. 33 Millar JS, Williams Vaughan EM. Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia. Br J Pharmacol. 1982; 75: 469– 478. 34 West TC, Amory DW. Single fiber recording of the effects of quinidine at atrial and pacemaker sites in the isolated right atrium of the rabbit. J Pharmacol Exp Therap. 1960; 130: 183– 193. 35 Cotoi S, Constantinescu L, Gavrilescu S. The effect of thyroid state on mono-phasic action potentials in human heart. Experientia. 1972; 28: 797– 798. 36 Freedberg AS, Papp JGy, Williams Vaughan EM. The effect of altered thyroid state on atrial intracellular potentials. J Physiol. 1970; 207: 357– 370. 37 Singh BN, Williams Vaughan EM. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol. 1970; 39: 657– 668. 38 Charlier R, Delaunois G, Bauthier J, Deltour G. Dans la série des benzofurannes. XL. Propriétés antiarrhythmiques de l'amiodarone. Cardiologia. 1969; 54: 83– 90. 39 Ferrero C, Abderhamane Ben M. Terapia medica del flutter atriale. G Ital Cardiol. 1972; 2: 186. 40 Rosenbaum MB, Chiale PA, Ryba D, Elizari MW. Control of tachyarrhythmias associated with the Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol. 1974; 34: 215– 223. 41 Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare dell'età pediatrica. Clin Pediatr. 1963; 45: 656. 42 Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc. 1964; 54: 103– 106. 43 Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation. 1978; 42: 1074– 1077. 44 Coltart DJ, Shand DG. Plasma propranolol levels in the quantitative assessment of β-adrenergic blockade in man. Br Med J. 1970; 3: 731– 734. 45 Williams Vaughan EM, Raine AEG, Cabrera AA, Whyte JM. The effects of prolonged β-adrenoceptor blockade on heart weight and cardiac intracellular potentials. Cardiovasc Res. 1975; 9: 579– 592. 46 Raine AEG, Williams Vaughan EM. Adaptational responses to prolonged beta adrenoceptor blockade in adult rabbits. Br J Pharmacol. 1980; 70: 205– 218. 47 Raine AEG, Williams Vaughan EM. Adaptation to prolonged beta-blockade of rabbit atrial, Purkinje and ventricular potentials, and of papillary muscle contraction. Time-course of development of, and recovery from, adaptation. Circ Res. 1980; 48: 804– 812. 48 Edvardsson N, Olsson SB. Effects of acute and chronic beta-receptor blockade on ventricular repolarisation in man. Br Heart J. 1981; 45: 628– 636. 49 Williams Vaughan EM, Hassan MO, Floras JS, Sleight P, Jones JV. Adaptation of hypertensives to treatment with cardio-selective and non-selective beta blockers. Absence of correlation between bradycardia and blood-pressure control, and reduction in slope of the QT/RR relation. Br Heart J. 1980; 44: 473– 487. 50 Govier WC, Mosal NC, Whittington P, Broom H. Myocardial alpha and beta adrenergic receptors as demonstrated by atrial functional refractory period changes. J Pharmacol Exp Therap. 1966; 154: 255– 263. 51 Giotti A, Ledda F, Mannaioni PF. Effects of noradrenaline and isopreneline in combination with α- and β-receptor blocking substances on the action potential of cardiac Purkinje fibres. J Physiol. 1973; 229: 99– 113. 52 Lefkowitz RJ, Haber E. A fraction of the ventricular myocardium that has the specificity of the cardiac beta-adrenergic receptor. Proc Natl Acad Sci USA. 1971; 68: 1773– 1777. 53 Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J. 1975; 89: 378– 390. 54 Wilhelmsson C, Vedin JA, Wilhelmsen L. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol: preliminary results. Lancet. 1974; 2: 1157– 1160. 55 Multicentre International Study. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Br Med J. 1977; 2: 419– 421. 56 The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981; 304: 801– 807. 57 Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1982; 247: 707– 1714. 58 Raine AEG, Williams Vaughan EM. Electrophysiological basis for the contrasting prophylactic efficacy of acute and prolonged beta-blockade. Br Heart J. 1978; 40(Suppl.): 71– 77. 59 Raine AEG, Williams Vaughan EM. Possible explanation for the protective action of long-term beta-adrenoceptor blockade after myocardial infarction. Br Heart J. 1976; 38: 873. 60 Tasgal J, Williams Vaughan EM. The effect of prolonged propranolol administration on myocardial transmural capillary density in young rabbits. J Physiol. 1981; 315: 353– 367. 61 Singh BN, Williams Vaughan EM. A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AH3474. Br J Pharmacol. 1970; 39: 675– 687. 62 Williams Vaughan EM, Salako L, Wittig JH. The effect on atrial and ventricular intracellular potentials, and other pharmacological actions of L9146, a non-halogenated benzo(b)-thiophene related to amiodarone. Cardiovasc Res. 1977; 11: 187– 197. 63 Noble D, Tsien RW. Outward membrane current activated in the plateau range of potentials in cardiac Purkinje fibres. J Physiol. 1969; 200: 205– 232. 64 Noble D, Tsien RW. Reconstruction of the repolarisation process in cardiac Purkinje fibres based on voltage clamp measurements of membrane current. J Physiol. 1969; 200: 233– 254. 65 Isenberg G. Is potassium conductance of cardiac Purkinje fibres controlled by [Ca2+]i? Nature. (Lond.) 1975; 253: 2783– 274. 66 Isenberg G. Cardiac Purkinje fibres: [Ca2+]i controls steady state potassium conductance. Pflügers Arch. 1977; 371: 71– 76. 67 Giebiksch G, Weidmann S. Membrane currents in mammalian ventricular heart muscle fibers using a voltage clamp technique. J Gen Physiol. 1971; 57: 290– 296. 68 Tillotson D. Inactivation of Ca conductance dependent on entry of Ca ions in molluscan neurons. Proc Natl Acad Sci USA. 1979; 76: 1497– 1500. 69 Mullins LJ. The generation of electric currents in cardiac fibers by Na/Ca exchange. Am J Physiol. 1979; 236: C103– C110. 70 Mullins LJ. Ion Transport in Heart. New York: Raven Press; 1981. 71 DiFrancesco D, Noble D. Implications of the re-interpretation of iK2 for the modelling of the electrical activity of pacemaker tissues in the heart. In: LN Bouman, HJ Jongsma, eds. Cardiac Rate and Rhythm. The Hague: Nijhoff; 1981: 95– 128. 72 Nathan AW, Hellestrand KJ, Bexton RS, Ward DE, Spurrell RAJ, Camm AJ. Electrophysiological effects of Sotalol—just another beta-blocker? Br Heart J. 1982; 47: 515– 520. 73 Bennett DH. Acute prolongation of myocardial refractoriness by Sotalol. Br Heart J. 1982; 47: 521– 526. 74 Wit AL, Steiner C, Damato AM. Electrophysiological effects of bretylium tosylate on single fibers of the canine specialized conduction system and ventricle. J Pharmacol Exp Therap. 1970; 173: 344– 356. 75 Papp JGy, Williams Vaughan EM. The effect of bretylium on intracellular cardiac action potentials in relation to its anti-arrhythmic and local anaesthetic activity. Br J Pharmacol. 1969; 37: 380– 390. 76 Millar JS, Williams Vaughan EM. Differential actions on rabbit nodal, atrial, Purkinje cell and ventricular potentials of melperone, a bradycardic agent delaying repolarization: effect of hypoxia. Br J Pharmacol. 1982; 75: 109– 121. 77 Mogelvang JC, Petersen EN, Folke PE, Ovesen L. Antiarrhythmic properties of a neuroleptic butyrophenone, melperone, in acute myocardial infarction. Acta Med Scand. 1980; 208: 61– 64. 78 Pantridge JF. Autonomic disturbance at the outset of acute myocardial infarction. In: PJ Schwartz, AN Brown, A Malliani, eds. Neural Mechanisms in Cardiac Arrhythmias. New York: Raven Press; 1978: 7– 17. 79 Fleckenstein A. Calcium Antagonism in Heart and Smooth Muscle. New York: Wiley; 1983. 80 Krikler DM, Goodwin JF. Cardiac Arrhythmias. London: Saunders; 1975. 81 Lown B. Electrical instability of the heart. In: DG Julian, MF Oliver, eds. Acute Myocardial Infarction. London: Livingstone; 1968: 84– 90. 82 Dahl G, Isenberg G. Decoupling of heart muscle cells: correlations with increased cytoplasmic calcium activity and with changes of nexus ultra-structure. J Membr Biol. 1980; 53: 63– 75. 83 El-Sherif N, Lazzara R. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 7. Effect of verapamil and D-600, and the role of the "slow inward current." Circulation. 1979; 60: 605– 615. 84 McKenna WJ, Harris L, Perez G, Krikler DM, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. II. Comparison of amiodarone and verapamil in treatment. Br Heart J. 1981; 46: 173– 178. 85 Williams Vaughan EM. QT and action potential duration. Br Heart J. 1982; 47: 513– 514. 86 Millar JS, Williams Vaughan EM. Pacemaker selectivity. Influence on rabbit atria of ionic environment and of alinidine, a possible anion antagonist. Cardiovasc. Res. 1981; 15: 335– 350. Citing Literature Volume24, Issue4April 1984Pages 129-147 This article also appears in:The Journal of Clinical Pharmacology: American College of Clinical Pharmacology 50th Anniversary Issue ReferencesRelatedInformation
Referência(s)